BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 2163053)

  • 1. Loss of heterozygosity in Wilms' tumour involves two distinct regions of chromosome 11.
    Wadey RB; Pal N; Buckle B; Yeomans E; Pritchard J; Cowell JK
    Oncogene; 1990 Jun; 5(6):901-7. PubMed ID: 2163053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferential loss of maternal alleles in sporadic Wilms' tumour.
    Pal N; Wadey RB; Buckle B; Yeomans E; Pritchard J; Cowell JK
    Oncogene; 1990 Nov; 5(11):1665-8. PubMed ID: 1980007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic mosaicism in normal tissues of Wilms' tumour patients.
    Chao LY; Huff V; Tomlinson G; Riccardi VM; Strong LC; Saunders GF
    Nat Genet; 1993 Feb; 3(2):127-31. PubMed ID: 8388768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular nature of genetic changes resulting in loss of heterozygosity of chromosome 11 in Wilms' tumours.
    Mannens M; Slater RM; Heyting C; Bliek J; de Kraker J; Coad N; de Pagter-Holthuizen P; Pearson PL
    Hum Genet; 1988 Dec; 81(1):41-8. PubMed ID: 2848758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of heterozygosity in Wilms' tumors, studied for six putative tumor suppressor regions, is limited to chromosome 11.
    Mannens M; Devilee P; Bliek J; Mandjes I; de Kraker J; Heyting C; Slater RM; Westerveld A
    Cancer Res; 1990 Jun; 50(11):3279-83. PubMed ID: 2159377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of heterozygosity for the short arm of chromosome 7 in sporadic Wilms tumour.
    Grundy RG; Pritchard J; Scambler P; Cowell JK
    Oncogene; 1998 Jul; 17(3):395-400. PubMed ID: 9690521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
    Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
    Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
    Grundy P; Telzerow P; Moksness J; Breslow NE
    Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular analysis of E-cadherin and cadherin-11 in Wilms' tumours.
    Schulz S; Becker KF; Braungart E; Reichmuth C; Klamt B; Becker I; Atkinson M; Gessler M; Höfler H
    J Pathol; 2000 Jun; 191(2):162-9. PubMed ID: 10861576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and cellular biology of Wilms' tumour.
    Maitland NJ; Brown KW; Poirier V; Shaw AP; Williams J
    Anticancer Res; 1989; 9(5):1417-26. PubMed ID: 2556071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of heterozygosity for chromosome region 11p15 in Wilms' tumours is not related to HRAS gene transforming mutations.
    Baird P; Wadey R; Cowell J
    Oncogene; 1991 Jul; 6(7):1147-9. PubMed ID: 1861864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p57K1P2 is expressed in Wilms' tumor with LOH of 11p15.5.
    Overall ML; Spencer J; Bakker M; Dziadek M; Smith PJ
    Genes Chromosomes Cancer; 1996 Sep; 17(1):56-9. PubMed ID: 8889507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial predisposition to Wilms' tumour does not map to the short arm of chromosome 11.
    Grundy P; Koufos A; Morgan K; Li FP; Meadows AT; Cavenee WK
    Nature; 1988 Nov; 336(6197):374-6. PubMed ID: 2848199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of allelic heterozygosity at a second locus on chromosome 11 in sporadic Wilms' tumor cells.
    Reeve AE; Sih SA; Raizis AM; Feinberg AP
    Mol Cell Biol; 1989 Apr; 9(4):1799-803. PubMed ID: 2542777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
    Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
    Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour.
    Ogawa O; Eccles MR; Szeto J; McNoe LA; Yun K; Maw MA; Smith PJ; Reeve AE
    Nature; 1993 Apr; 362(6422):749-51. PubMed ID: 8097018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The familial Wilms' tumour susceptibility gene, FWT1, may not be a tumour suppressor gene.
    Rahman N; Arbour L; Tonin P; Baruchel S; Pritchard-Jones K; Narod SA; Stratton MR
    Oncogene; 1997 Jun; 14(25):3099-102. PubMed ID: 9223674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome.
    Grundy PE; Telzerow PE; Breslow N; Moksness J; Huff V; Paterson MC
    Cancer Res; 1994 May; 54(9):2331-3. PubMed ID: 8162576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A third Wilms' tumor locus on chromosome 16q.
    Maw MA; Grundy PE; Millow LJ; Eccles MR; Dunn RS; Smith PJ; Feinberg AP; Law DJ; Paterson MC; Telzerow PE
    Cancer Res; 1992 Jun; 52(11):3094-8. PubMed ID: 1317258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of heterozygosity at 11p13 in Wilms' tumours does not necessarily involve mutations in the WT1 gene.
    Cowell JK; Groves N; Baird P
    Br J Cancer; 1993 Jun; 67(6):1259-61. PubMed ID: 8390282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.